Federated Hermes’s aTyr Pharma ATYR Stock Holding History

Federated Hermes’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.08M	Sell	8,509,678 -2,000,000	-19%	-$1.31M	0.01%	840
2026 Q1	$8.2M	Hold	10,509,678	–	–	0.01%	691
2025 Q4	$8.23M	Sell	10,509,678 -34,759	-0.3%	-$28.5K	0.01%	683
2025 Q3	$7.61M	Sell	10,544,437 -4,122,163	-28%	-$18.7M	0.01%	636
2025 Q2	$74.4M	Hold	14,666,600	–	–	0.14%	181
2025 Q1	$44.3M	Hold	14,666,600	–	–	0.1%	255
2024 Q4	$53.1M	Hold	14,666,600	–	–	0.12%	226
2024 Q3	$25.8M	Hold	14,666,600	–	–	0.06%	369
2024 Q2	$22.9M	Buy	14,666,600 +4,497,000	+44%	+$7.82M	0.05%	376
2024 Q1	$19.8M	Hold	10,169,600	–	–	0.05%	417
2023 Q4	$14.3M	Hold	10,169,600	–	–	0.04%	469
2023 Q3	$16.1M	Sell	10,169,600 -20,366	-0.2%	-$37.7K	0.04%	417
2023 Q2	$22M	Hold	10,189,966	–	–	0.05%	355
2023 Q1	$21.4M	Buy	10,189,966 +4,958,366	+95%	+$10.9M	0.05%	374
2022 Q4	$11.5M	Buy	5,231,600 +9,350	+0.2%	+$22K	0.03%	507
2022 Q3	$15.7M	Hold	5,222,250	–	–	0.05%	434
2022 Q2	$14.8M	Hold	5,222,250	–	–	0.04%	458
2022 Q1	$27.9M	Hold	5,222,250	–	–	0.06%	367
2021 Q4	$39M	Hold	5,222,250	–	–	0.07%	323
2021 Q3	$47.4M	Buy	5,222,250 +3,607,250	+223%	+$21.6M	0.09%	278
2021 Q2	$7.88M	Hold	1,615,000	–	–	0.01%	722
2021 Q1	$7.19M	Hold	1,615,000	–	–	0.01%	755
2020 Q4	$6.27M	Hold	1,615,000	–	–	0.01%	749
2020 Q3	$5.22M	Hold	1,615,000	–	–	0.01%	719
2020 Q2	$7.17M	Hold	1,615,000	–	–	0.02%	620
2020 Q1	$4.52M	Buy	1,615,000 +1,019,928	+171%	+$4.4M	0.01%	654
2019 Q4	$2.48M	Buy	595,072 +45,072	+8%	+$174K	0.01%	959
2019 Q3	$1.93M	Buy	550,000 +21,877	+4%	+$80.6K	﹤0.01%	1045
2019 Q2	$2.71M	Buy	+528,123	New	+$3.59M	0.01%	964
2018 Q1	–	Sell	-14	Closed	-$1K	–	2243
2017 Q4	$1K	Sell	14 -6	-30%	-$369	﹤0.01%	2135
2017 Q3	$1K	Sell	20 -3	-13%	-$139	﹤0.01%	2104
2017 Q2	$1K	Hold	23	–	–	﹤0.01%	2101
2017 Q1	$1K	Sell	23 -30	-57%	-$1.37K	﹤0.01%	2096
2016 Q4	$2K	Sell	53 -39,897	-100%	-$1.64M	﹤0.01%	2025
2016 Q3	$1.78M	Buy	39,950 +13,554	+51%	+$586K	0.01%	899
2016 Q2	$1.03M	Buy	26,396 +24,482	+1,279%	+$1.14M	﹤0.01%	1089
2016 Q1	$106K	Sell	1,914 -9,607	-83%	-$730K	﹤0.01%	1561
2015 Q4	$1.59M	Hold	11,521	–	–	0.01%	967
2015 Q3	$1.66M	Hold	11,521	–	–	0.01%	935
2015 Q2	$2.99M	Buy	+11,521	New	+$3.58M	0.01%	771

Other funds holding ATYR

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kalehua Capital Management Dallas, Texas $174M AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Federated Hermes's ATYR Position: Q2 2026 in Review

Federated Hermes reduced its aTyr Pharma (ATYR) stake by 19% in Q2 2026, selling an estimated $1.31M and leaving 8,509,678 shares worth $5.08M. The position accounts for 0.01% of the portfolio, ranked #840.

Federated Hermes first reported a position in ATYR in Q2 2015 and has held it in 40 quarters since. The position peaked at $74.4M in Q2 2025. 90 funds tracked by Wall St. Rank hold ATYR as of Q2 2026.

Federated Hermes held 8,509,678 shares of aTyr Pharma worth $5.08M as of Q2 2026.
Federated Hermes sold 2,000,000 aTyr Pharma shares in Q2 2026, an estimated $1.31M.
aTyr Pharma made up 0.01% of Federated Hermes's portfolio in Q2 2026, its #840 holding.
Federated Hermes first reported a position in aTyr Pharma in Q2 2015 and has held it in 40 quarters since.
Federated Hermes's aTyr Pharma position peaked at $74.4M in Q2 2025.
90 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.